Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2072 Tablets

9 juni 2026 uppdaterad av: InnovStone Therapeutics Limited

A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SYH2072 Tablets in Healthy Participants

This is a first-in-human study to evaluate the safety, tolerability, PK, and PD characteristics of SYH2072 Tablets after single and multiple oral doses in healthy participants.

Studieöversikt

Status

Rekrytering

Betingelser

Studietyp

Interventionell

Inskrivning (Beräknad)

112

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

  • Namn: Clinical Trials Information Group officer
  • Telefonnummer: +86-0311-69085587
  • E-post: ctr-contact@cspc.cn

Studieorter

    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100029
        • Rekrytering
        • Beijing AnZhen Hospital, Capital Medical University
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen

Tar emot friska volontärer

Ja

Beskrivning

Inclusion Criteria:

  1. Participants must be fully informed about the study content, procedures, and potential adverse reactions, and voluntarily sign the written informed consent form (ICF) before the study;
  2. Sex: Male or female;
  3. Age: 18-55 years old (inclusive);
  4. Body mass index in the range of 19 to 30 kg•m-2 [Body Mass Index (BMI) = weight/height2 (kg•m^2)] (inclusive), with a body weight of no less than 50 kg for males (inclusive) and no less than 45 kg for females (inclusive);
  5. Participants are able to communicate well with the investigator and are able to complete the study in accordance with the protocol.

Exclusion Criteria:

  1. History of severe allergic diseases or allergic constitution (allergy to ≥ 3 drugs or foods);
  2. Use of corticosteroid drugs within 3 months prior to screening;
  3. Past and/or current clinically significant medical conditions, including but not limited to diseases of the circulatory, hematologic or hematopoietic, respiratory, endocrine, urinary, digestive, nervous or psychiatric systems, infections, tumors, severe trauma, or any other disease that the investigator considers should be excluded or may interfere with the interpretation of the study results;
  4. Postural tachycardia (heart rate increase > 30 beats/minute upon standing) or postural hypotension (decrease in SBP ≥ 20mmHg or DBP ≥ 10mmHg upon standing) at screening;
  5. Have undergone major surgery within 6 months prior to screening, or plan to undergo major surgery during the study;
  6. Potassium ion level outside the normal range in clinical chemistry tests at screening, or serum creatinine > upper limit of normal (ULN);
  7. Any one of the following at screening: alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), gamma-glutamyl transferase (GGT), or alkaline phosphatase (ALP) > 1.2×ULN (one re-test within 1 week is allowed);
  8. Estimated glomerular filtration rate (eGFR) < 90mL/min/1.73 m2 at screening;
  9. Prolonged QT/QTc interval at screening (QTcF ≥ 450ms for males, ≥ 470ms for females);
  10. Positive for any of the following: HBsAg, HCV antibody, syphilis antibody, or HIV antibody;
  11. Blood loss or blood donation exceeding 200mL within 3 months prior to screening (excluding menstruation for females), and/or platelet donation within 2 weeks;
  12. Use of any prescription drugs, over-the-counter drugs, Chinese herbal medicines, or dietary supplements (including vitamins, health products, etc.) within 28 days prior to screening;
  13. History of drug abuse, and/or use of illicit drugs within 3 months prior to screening, and/or habitual use of any psychotropic drugs, including Chinese herbal medicines, and/or a positive urine drug screen;
  14. Average daily smoking of more than 5 cigarettes (or an equivalent amount of tobacco in e-cigarettes) within 3 months prior to screening, and/or unwilling to avoid using any tobacco products during the study;
  15. Regular alcohol consumption within 6 months prior to screening, defined as more than 14 units of alcohol per week (1 unit = 360mL of 5% alcohol beer or 45mL of 40% alcohol spirits or 150mL of 12% alcohol wine), and/or inability to abstain from alcohol intake during the study, and/or a positive breath alcohol test;
  16. Excessive daily consumption of tea, coffee, and/or caffeinated beverages (8 cups or more, 1 cup = 250mL) within 1 month prior to screening, and/or unwilling to abstain from tea, coffee, and/or caffeinated foods, grapefruit and/or grapefruit juice, and/or poppy-containing products during the study;
  17. Having a fertility plan (including sperm or egg donation) from the time of signing the ICF until 3 months after the last dose, and/or unwilling to use an effective non-drug method of contraception;
  18. Participation in any clinical study within 3 months prior to screening;
  19. Participants who may be unable to complete the study for other reasons or who are deemed unsuitable for inclusion by the investigator.

    In addition to the above requirements, female participants who meet the following criteria will also be excluded:

  20. Pregnant or lactating women;
  21. Use of oral contraceptives within 28 days prior to screening;
  22. Use of long-acting estrogen and/or progestogen injections and/or implants within 6 months prior to screening; 23)Women of childbearing potential who have had unprotected sexual intercourse with a partner within 28 days prior to dosing.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Single Ascending Doses (SAD, Part A)
In this part, 6 ascending dose cohorts (10 participants per cohort) will be studied. Within each cohort, participants will be randomized in a 4:1 ratio to receive either SYH2072 or placebo.
SYH2072 tablets will be administered as a single or multiple oral doses.
SYH2072 placebo tablets will be administered as a single or multiple oral doses.
Experimentell: Food Effect (FE, Part B)
12 participants and single dose food effect cohort.
SYH2072 tablets will be administered as a single or multiple oral doses.
Experimentell: Experimental: Multiple Ascending Doses (MAD, Part C)
In this part, 4 ascending dose cohorts (10 participants per cohort) will be studied. Within each cohort, participants will be randomized in a 4:1 ratio to receive either SYH2072 or placebo.
SYH2072 tablets will be administered as a single or multiple oral doses.
SYH2072 placebo tablets will be administered as a single or multiple oral doses.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
The rate of Adverse events
Tidsram: Through study completion, an average of 8 months
The rate of Adverse events occur during the whole study
Through study completion, an average of 8 months
The rate of normality or abnormality of electrocardiogram
Tidsram: Through study completion, an average of 8 months
The rate of normality or abnormality of electrocardiogram during the whole study
Through study completion, an average of 8 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

15 januari 2026

Primärt slutförande (Beräknad)

1 februari 2027

Avslutad studie (Beräknad)

1 april 2027

Studieregistreringsdatum

Först inskickad

8 maj 2026

Först inskickad som uppfyllde QC-kriterierna

9 juni 2026

Första postat (Faktisk)

15 juni 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

15 juni 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

9 juni 2026

Senast verifierad

1 maj 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • SYH2072-001

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera